Diagnostic procedures for non-small-cell lung cancer (NSCLC): Recommendations of the European Expert Group

Thorax

Volumn 71, Issue 2, 2016, Pages 177-184

  Dietel, Manfred ^a   Bubendorf, Lukas ^b   Dingemans, Anne Marie C ^c   Dooms, Christophe ^d   Elmberger, Göran ^e   García, Rosa Calero ^f   Kerr, Keith M ^g   Lim, Eric ^h   López Ríos, Fernando ⁱ   Thunnissen, Erik ^j   Van Schil, Paul E ^k   Von Laffert, Maximilian ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g UNIVERSITY OF ABERDEEN   (United Kingdom)

^h ROYAL BROMPTON HOSPITAL   (United Kingdom)

ⁱ Hospital Universitario HM Sanchinarro   (Spain)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^k ANTWERP UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; ROS PROTOONCOGENE 1; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CONSENSUS DEVELOPMENT; CYTOPATHOLOGY; DIAGNOSTIC PROCEDURE; EUROPE; FIBEROPTIC BRONCHOSCOPY; FINE NEEDLE ASPIRATION BIOPSY; FLUORESCENCE IN SITU HYBRIDIZATION; GOOD CLINICAL PRACTICE; HEALTH CARE QUALITY; HOSPITAL INFORMATION SYSTEM; HUMAN; IMAGE GUIDED BIOPSY; IMMUNOHISTOCHEMISTRY; INFORMATION PROCESSING; LUNG BIOPSY; LUNG PARENCHYMA; MOLECULAR DIAGNOSIS; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PERCUTANEOUS BIOPSY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUALITY CONTROL; REVIEW; STANDARDIZATION; TISSUE PRESERVATION; WORKFLOW; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC IMAGING; LUNG NEOPLASMS; MEDICAL SOCIETY; PRACTICE GUIDELINE; STANDARDS;

CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC IMAGING; EUROPE; HUMANS; LUNG NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 84958983242     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-206677     Document Type: Review

References (49)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
2. Thunnissen E, Bubendorf L, Dietel M, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 2012;461:245-57.
3. Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 2012;18:4570-9.
4. Ou SH, Camidge DR, Riely G. Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Ann Oncol 2013;24 (Suppl 9):ix43.
5. Dietel M, Johrens K, Laffert M, et al. Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther 2013;20:211-21.
6. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 2011;8:381-5.
7. McCloskey P, Balduyck B, Van Schil PE, et al. Radical treatment of non-small cell lung cancer during the last 5 years. Eur J Cancer 2013;49:1555-64.
8. Annema JT, van Meerbeeck JP, Rintoul RC, et al. Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA 2010;304:2245-52.
9. De Leyn P, Dooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg 2014;45:787-98.
10. Hetzel J, Eberhardt R, Herth FJ, et al. Cryobiopsy increases the diagnostic yield of endobronchial biopsy: a multicentre trial. Eur Respir J 2012;39:685-90.
11. Du Rand IA, Blaikley J, Booton R, et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax 2013;68 (Suppl 1):i1-44.
12. Popovich J Jr, Kvale PA, Eichenhorn MS, et al. Diagnostic accuracy of multiple biopsies from flexible fiberoptic bronchoscopy. A comparison of central versus peripheral carcinoma. Am Rev Respir Dis 1982;125:521-3.
13. Dooms C, Muylle I, Yserbyt J, et al. Endobronchial ultrasound in the management of non small cell lung cancer. Eur Respir Rev 2013;22:169-77.
14. Wu CC, Maher MM, Shepard JA. CT-guided percutaneous needle biopsy of the chest: preprocedural evaluation and technique. AJR Am J Roentgenol 2011;196: W511-14.
15. Kothary N, Lock L, Sze DY, et al. Computed tomography-guided percutaneous needle biopsy of pulmonary nodules: impact of nodule size on diagnostic accuracy. Clin Lung Cancer 2009;10:360-3.
16. Westra WH, Hruban RH, Phelps TH, et al. Surgical pathology dissection: an illustrated guide. 2nd edn. New York, NY: Springer-Verlag, 2003.
17. Wittekind C, Meyer HJ. TNM classification of malignant tumours. 7th edn. New York, NY: Wiley-Blackwell, 2011:336.
18. Kerr KM, Bubendorf L, Edelman MJ, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 2014;25:1681-90.
19. Tsao MH, Hirsch FR, Yatabe Y, eds. IASLC atlas of ALK testing in lung cancer. Aurora, CO: International Association for the Study of Lung Cancer, 2013.
20. Bussolati G, Annaratone L, Medico E, et al. Formalin fixation at low temperature better preserves nucleic acid integrity. PLoS ONE 2011;6:e21043.
21. Muller BM, Brase JC, Haufe F, et al. Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections. J Clin Pathol 2012;65:660-2.
22. von Laffert M, Warth A, Penzel R, et al. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. J Thorac Oncol 2014;9:1685-92.
23. Conde E, Angulo B, Izquierdo E, et al. Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers. Clin Transl Oncol 2013;15:503-8.
24. Lee HJ, Seol HS, Kim JY, et al. ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms. Ann Surg Oncol 2013;20:200-8.
25. Sekine I, Yamamoto N, Nishio K, et al. Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008;99:1757-62.
26. Conde E, Suarez-Gauthier A, Benito A, et al. Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. PLoS ONE 2014;9:e107200.
27. Fu S, Wang F, Shao Q, et al. Detection of EML4-ALK fusion gene in Chinese non-small cell lung cancer by using a sensitive quantitative real-time reverse transcriptase PCR technique. Diagn Mol Pathol 2015;23:245-54.
28. Li T, Maus MK, Desai SJ, et al. Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol 2014;9:18-25.
29. Lira ME, Choi YL, Lim SM, et al. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. J Mol Diagn 2014;16:229-43.
30. Zhang NN, Liu YT, Ma L, et al. The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy. PLoS ONE 2014;9:e84501.
31. Pan Y, Zhang Y, Li Y, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion patternspecific clinicopathologic, histologic and cytologic features. Lung Cancer 2014;84:121-6.
32. Wang R, Pan Y, Li C, et al. The use of quantitative real-time reverse transcriptase PCR for 50 and 30 portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res 2012;18:4725-32.
33. Huang D, Kim DW, Kotsakis A, et al. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. Genomics 2013;102:157-62.
34. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
35. Knoepp SM, Roh MH. Ancillary techniques on direct-smear aspirate slides: a significant evolution for cytopathology techniques. Cancer Cytopathol 2013;121:120-8.
36. Savic S, Bubendorf L. Role of fluorescence in situ hybridization in lung cancer cytology. Acta Cytol 2012;56:611-21.
37. Savic S, Bode B, Diebold J, et al. Detection of ALK-positive non-small-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5A4 clone. J Thorac Oncol 2013;8:1004-11.
38. Kassahn KS, Scott HS, Caramins MC. Integrating massively parallel sequencing into diagnostic workflows and managing the annotation and clinical interpretation challenge. Hum Mutat 2014;35:413-23.
39. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013;137:828-60.
40. Deans ZC, Bilbe N, O'Sullivan B, et al. Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment. J Clin Pathol 2013;66:319-25.
41. Normanno N, Pinto C, Taddei G, et al. Results of the First Italian External Quality Assurance Scheme for somatic EGFR mutation testing in non-small-cell lung cancer. J Thorac Oncol 2013;8:773-8.
42. Thunnissen E, Bovee JV, Bruinsma H, et al. EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy. J Clin Pathol 2011;64:884-92.
43. von Laffert M, Penzel R, Schirmacher P, et al. Multicenter ALK testing in non-small-cell lung cancer: results of a round robin test. J Thorac Oncol 2014;9:1464-9.
44. von Laffert M, Warth A, Penzel R, et al. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. Lung Cancer 2013;81:200-6.
45. van Krieken JH, Normanno N, Blackhall F, et al. Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch 2013;462:27-37.
46. Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014;46:225-33.
47. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012;72:4875-82.
48. Taniguchi K, Okami J, Kodama K, et al. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 2008;99:929-35.
49. Camidge DR, Skokan M, Kiatsimkul P, et al. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy. Cancer 2013;119:3968-75.